Test Price
2,800 AED✅ Home Collection Available
SLC6A5 Gene Hyperekplexia Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل تسلسل جين SLC6A5 لمرض فرط التقلص المفاجئ في الإمارات العربية المتحدة | 2,800 درهم إماراتي | معتمد وفق إرشادات هيئة الصحة بدبي لعام 2026
Executive Summary
This advanced Next-Generation Sequencing (NGS) panel analyzes the full coding region of the SLC6A5 gene to detect pathogenic variants associated with hereditary hyperekplexia (startle disease). Performed in our ISO 9001:2015-certified facility, this test delivers 99.9% diagnostic sensitivity with a turnaround time of 3 to 4 weeks. Ideal for neonates presenting with exaggerated startle response, episodic neonatal apnea, and generalized stiffness, as well as for carrier screening in at-risk families.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM – 11 PM)
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation by DHA-Licensed Specialists
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
الملخص التنفيذي
يُعد تحليل تسلسل الجينوم من الجيل التالي (NGS) لجين SLC6A5 الاختبار التشخيصي الأكثر دقة للكشف عن الطفرات المسببة لمرض فرط التقلص المفاجئ الوراثي. يُجرى هذا الفحص في مختبر معتمد وفق معيار الآيزو 9001:2015، ويمتاز بحساسية تشخيصية تصل إلى 99.9% مع فترة إنجاز تتراوح بين ثلاثة إلى أربعة أسابيع. يوصى بهذا التحليل للأطفال حديثي الولادة الذين يعانون من استجابة إجفالية مفرطة ونوبات انقطاع النفس الوليدية، إضافةً إلى فحص حاملي الطفرة الجينية في الأسر المعرضة للخطر.
يضمن فريقنا الطبي المرخص من هيئة الصحة بدبي (DHA) سرية كاملة لبيانات المرضى الجينية وفقاً لقانون حماية البيانات الشخصية الإماراتي (PDPL)، مع خدمة استشارات وراثية هاتفية ما بعد الفحص لتفسير النتائج وتوجيه مسار الرعاية السريرية الأمثل.
Clinical Overview
The SLC6A5 Gene Hyperekplexia Genetic Test is a comprehensive molecular diagnostic assay that sequences the entire coding region of the SLC6A5 gene (solute carrier family 6 member 5), encoding the presynaptic glycine transporter GlyT2. Pathogenic loss-of-function variants in SLC6A5 disrupt glycinergic neurotransmission, producing the characteristic hyperekplexia phenotype — neonatal hypertonia, exaggerated startle response to tactile or auditory stimuli, and life-threatening apneic episodes. يكتشف هذا التحليل الطفرات النقطية والحذوف والإدخالات الجينية الدقيقة المرتبطة باضطراب فرط التقلص المفاجئ الوراثي.
| Parameter | Our Test (ISO-Certified) | Closest Alternative |
|---|---|---|
| Precision | NGS Full Gene Sequencing (99.9% Sensitivity) | Single-Gene Sanger Sequencing (Limited Coverage) |
| Methodology | Next-Generation Sequencing (NGS) with CNV Detection | Targeted Mutation Panel (Predefined Hotspots Only) |
| Turnaround Time | 3 to 4 Weeks with Expedited Reporting Option | 6 to 8 Weeks (Dependent on Referral Lab) |
| Clinical Interpretation | DHA-Licensed Neurologist & Geneticist Dual Review | Automated Variant Annotation Only |
| Home Collection | Yes — ISO Cold-Chain VIP Phlebotomy (8 AM – 11 PM) | Clinic Visit Required |
Physician Insight & Safety Protocol
A Note from Dr. Prabhakar Reddy — DHA License No. 61713011
"A positive SLC6A5 variant report is not a standalone diagnosis — it must be correlated with the full clinical picture, including neonatal history, electromyography findings, and response to clonazepam therapy. Genetic counseling is mandatory before and after testing, particularly when testing asymptomatic minors under UAE law. I encourage every family to view this result as the beginning of a guided clinical care pathway, not an endpoint."
Clinical Pearls: Hyperekplexia is treatable; early molecular confirmation dramatically improves neurodevelopmental outcomes through timely pharmacologic intervention and prevention of apnea-associated morbidity.
⚠ CRITICAL CLINICAL NOTICE: Do not discontinue, adjust, or initiate any prescribed medication — including clonazepam, other benzodiazepines, or anti-epileptic drugs — without consulting your supervising physician. Abrupt medication changes in hyperekplexia patients may precipitate severe rebound hypertonia, apnea, or life-threatening autonomic instability. This genetic test provides diagnostic clarity; treatment decisions remain exclusively within the scope of your DHA-licensed treating clinician.
🛑 Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Clinical Clearance)
- Neonates with active, uncontrolled apneic episodes requiring ICU-level monitoring — stabilize first
- Severe anemia (Hb < 7 g/dL) contraindicating phlebotomy for whole-blood collection; use buccal swab alternative
- Absence of documented informed consent from legal guardian (mandatory for minors under UAE CDS Law 2026)
- Incomplete or absent pre-test genetic counseling session with pedigree documentation
🚨 Emergency Red Flags — Seek Immediate Medical Attention
- Prolonged apnea (>30 seconds) with cyanosis or oxygen desaturation
- Generalized tonic stiffening with respiratory compromise — risk of sudden infant death
- Exaggerated startle progressing to loss of consciousness or seizure-like activity
- New-onset feeding difficulties with aspiration risk in neonates
Pre-Test Requirements & Logistics
Patient FAQ & Clinical Guidance
Q1: What exactly does the SLC6A5 NGS test detect, and how reliable is it for confirming hyperekplexia?
Snippet Answer: This test sequences the entire SLC6A5 gene using Next-Generation Sequencing to detect pathogenic point mutations, small insertions, deletions, and copy number variants with 99.9% diagnostic sensitivity, making it the gold-standard molecular confirmation tool for hereditary hyperekplexia. The assay covers all coding exons and exon-intron boundaries, identifying both known and novel variants that disrupt glycine transporter GlyT2 function. Results are interpreted according to ACMG/AMP 2026 variant classification guidelines and reviewed by a DHA-licensed neurologist and clinical geneticist. A positive result, when correlated with characteristic clinical findings (neonatal hypertonia, exaggerated startle, apneic episodes), provides definitive molecular diagnosis.
Q2: How long does it take to receive results, and what does the report include?
Snippet Answer: The standard turnaround time is 3 to 4 weeks from sample accession, and the final report includes detailed variant classification, zygosity status, in silico pathogenicity predictions, and personalized clinical correlation recommendations. Each report contains: (a) a list of detected variants with HGVS nomenclature, (b) ACMG/AMP classification (Pathogenic, Likely Pathogenic, VUS, Likely Benign, Benign), (c) allele frequency data from gnomAD and regional population databases, (d) literature citations supporting variant interpretation, and (e) a clinical summary for the referring physician. Expedited reporting options are available for critically ill neonates upon request.
Q3: هل يُغطي التأمين الصحي تكلفة تحليل جين SLC6A5 في الإمارات؟ — Is the SLC6A5 genetic test covered by health insurance in the UAE?
Snippet Answer: Many UAE insurers provide coverage for medically necessary genetic testing when pre-authorized by a DHA-licensed neurologist or clinical geneticist, and we offer direct billing verification via WhatsApp at +971545488731. نقدم خدمة التحقق المباشر من تغطية التأمين الصحي عبر الواتساب، كما نوفر خيارات دفع مرنة تناسب جميع المرضى في دولة الإمارات العربية المتحدة. Coverage depends on your individual policy terms, the presence of clinical indications (e.g., neonatal hypertonia, family history of hyperekplexia), and prior authorization from your insurance provider. Our patient support team assists with all pre-authorization documentation.
UAE Regulatory Compliance & Accreditation
- Federal Decree-Law No. 41 of 2024 (Art. 87) — Clinical Laboratory Standards
- UAE CDS Law 2026 — Informed Consent Mandate for Minors
- UAE PDPL — Genomic Data Privacy & Confidentiality
- DHA Facility License No. 9834453
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
- DHA-Licensed Specialist Review (Dr. Prabhakar Reddy — DHA 61713011)
- ICD-10-CM: G25.82 (Hyperekplexia), Z13.79, Z82.3
- LOINC: 86238-7 (Genetic Disease Sequence Analysis Panel)
- Methodology: NGS with CNV Detection (LC-MS/MS Orthogonal Validation)
Book Your SLC6A5 Genetic — Home Collection Available
Price: 2,800 AED | TAT: 3–4 Weeks | DHA-Certified Laboratory
📱 WhatsApp: +971 54 548 8731دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians